Bioneercorporation바이오니아
064550 · KOSDAQ · ₩064550 · 바이오니아
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩6,256
vs the current price (₩7,070)
- Enterprise value
- ₩129B
- Equity value
- ₩161B
- WACC
- 7.3%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Bear / Base / Bull
- Bear
- ₩1,297
- −81.7%
- Base
- ₩6,256
- −11.5%
- Bull
- ₩15,328
- +116.8%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (3.0%).
Revenue growth
- 14.8%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (14.8% a year, annual reports), fading to 3% by year 5.
- 11.8%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (14.8% a year, annual reports), fading to 3% by year 5.
- 8.9%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (14.8% a year, annual reports), fading to 3% by year 5.
- 5.9%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (14.8% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (14.8% a year, annual reports), fading to 3% by year 5.
Business
- 3%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 2.4%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 3%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 12.9%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.03%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-27.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.22, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.53%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩346B
- Net debt (borrowings and leases − cash and deposits)
- −₩38B
- + Stakes and investments
- ₩7.5B
- Associates, long-term financial assets and deposits (book value)
- − Minority interests
- ₩14B
- Shares
- 25,810,291
- Share price
- ₩7,070
- Market cap
- ₩182B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩263B | ₩294B | ₩330B | ₩397B | ₩444B | ₩483B | ₩512B | ₩527B |
| Growth | 20.5% | 11.7% | 12.3% | 14.8% | 11.8% | 8.9% | 5.9% | 3.0% |
| EBIT | ₩792M | −₩13B | ₩15B | ₩12B | ₩13B | ₩15B | ₩15B | ₩16B |
| EBIT margin | 0.3% | −4.6% | 4.6% | 3.0% | 3.0% | 3.0% | 3.0% | 3.0% |
| After-tax EBIT | ₩574M | −₩9.7B | ₩11B | ₩8.6B | ₩9.7B | ₩11B | ₩11B | ₩11B |
| + Depreciation | — | — | — | ₩9.5B | ₩11B | ₩12B | ₩12B | ₩13B |
| − Capital spending | ₩5.5B | ₩14B | ₩7.2B | ₩12B | ₩13B | ₩15B | ₩15B | ₩16B |
| − Working capital | −₩15B | −₩38B | ₩11B | ₩6.6B | ₩6B | ₩5.1B | ₩3.7B | ₩2B |
| Free cash flow | — | — | — | −₩350M | ₩948M | ₩2.5B | ₩4.4B | ₩6.3B |
| Discount factor | — | — | — | 0.932 | 0.868 | 0.809 | 0.753 | 0.702 |
| Present value | — | — | — | −₩326M | ₩823M | ₩2B | ₩3.3B | ₩4.4B |
Terminal value ₩169B, worth ₩119B today: 92% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩7,904 a share)Now 0.89× | ₩10,2551.30× | ₩24,7383.13× | ₩46,3985.87× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.3% | ₩6,812 | ₩7,168 | ₩7,605 | ₩8,153 | ₩8,862 |
| 6.8% | ₩6,254 | ₩6,529 | ₩6,860 | ₩7,264 | ₩7,771 |
| 7.3% | ₩5,786 | ₩6,002 | ₩6,256 | ₩6,560 | ₩6,933 |
| 7.8% | ₩5,388 | ₩5,559 | ₩5,757 | ₩5,991 | ₩6,271 |
| 8.3% | ₩5,046 | ₩5,182 | ₩5,338 | ₩5,520 | ₩5,734 |
Now (TTM)
- Market cap
- ₩182B
- Enterprise value
- ₩142B
- P/E
- —
- P/B
- 0.9×
- P/S
- 0.5×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩12,750 | ₩18,850 | ₩33,300 | ₩29,400 | ₩48,600 |
| Market cap | ₩329B | ₩487B | ₩859B | ₩759B | ₩1.3T |
| P/E | — | — | — | 62.8× | 46.2× |
| P/B | 1.6× | 2.3× | 3.8× | 3.2× | 6.2× |
| P/S | 1.0× | 1.7× | 3.3× | 3.5× | 5.6× |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 0.0% | — | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Bioneercorporation | — | 0.9× | 0.5× | — | 0.0% |
| Samsung Biologics | 32.1× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.8× | 2.4× | 8.9× | — | 0.0% |
| Alteogen | 78.8× | 28.4× | 59.9× | — | 0.1% |
| Yuhan | 24.8× | 2.5× | 2.6× | 32.5× | 0.8% |
| SK biopharmaceuticals | 14.6× | 5.7× | 6.8× | — | 0.0% |
| HLB | — | 15.4× | 54.6× | — | 0.0% |
| Similar companies (median) | 27.8× | 6.7× | 11.5× | 32.5× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Bioneercorporation / 바이오니아 / 064550 / KRX:064550
Source: KRX statistical information